Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, <i>in-vitro</i> and <i>in vivo</i> study
Qingqing Luo, Jingjing Yang, Haohang Xu, Jieran Shi, Zhen Liang, Rui Zhang, Ping Lü, Guojuan Pu, Ningmin Zhao, Junjie Zhang
Abstract
) over 12 h in rabbit cornea and conjunctiva, respectively, treated with one dose of SRB-NLC compared with those treated with SRB suspension. Moreover, SRB-NLC (0.05% SRB) and dexamethasone (0.025%) similarly suppressed corneal neovascularization in mice. In conclusion, the optimized SRB-NLC formulation demonstrated excellent physicochemical properties and good tolerance, sustained release, and enhanced ocular bioavailability. It is safe and potentially effective for the treatment of corneal neovascularization.
Topics & Concepts
Corneal neovascularizationIn vivoBioavailabilityCorneaPharmacologySorafenibPharmacokineticsNeovascularizationMaterials scienceBiomedical engineeringAngiogenesisChemistryMedicineOphthalmologyCancer researchBiologyBiotechnologyHepatocellular carcinomaAdvanced Drug Delivery SystemsOcular Surface and Contact LensCorneal Surgery and Treatments